New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
19:04 EDTMNOVMedicNova announces positive interim results of MN-166 phase 2a study
MediciNova announced positive interim results of a phase 2a clinical trial of MN-166 in opioid dependence. The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Dr. Sandra Comer, Professor of Neurobiology. The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit. MN-166 demonstrated a number of beneficial effects on the subjective, analgesic, and reinforcing effects of oxycodone. MN-166 significantly decreased the craving for heroin, cocaine, and tobacco. MN-166 also decreased the positive subjective effects of oxycodone measured by mean responses to statements such as "I Feel High" and "I Liked the Dose." MN-166 also enhanced the analgesic effects of oxycodone. MN-166 reduced the sum score on the McGill Pain Questionnaire, reduced the mean rating on the Painful scale, and reduced the mean rating on the Bothersome scale. Finally, MN-166 decreased the reinforcing effects of oxycodone.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
09:19 EDTMNOVOn The Fly: Pre-market Movers
Subscribe for More Information
August 18, 2015
19:48 EDTMNOVMediciNova 5M share Spot Secondary priced at $3.50
Subscribe for More Information
18:32 EDTMNOVOn The Fly: After Hours Movers
Subscribe for More Information
16:01 EDTMNOVMediciNova files to sell common stock, no amount given
MediciNova intends to use the net proceeds received from this offering to fund continued research and development efforts, including with respect to its MN-166 and MN-001 product candidates, and for general corporate purposes, including working capital. Ladenburg Thalmann is acting as sole book-running manager of the offering, and Mizuho Securities and SMBC Nikko are acting as co-managers of the offering.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use